Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro

Cancer Research

Volumn 61, Issue 1, 2001, Pages 131-137

  End, David W ^d   Smets, Gerda ^b   Todd, Alison V ^c   Applegate, Tanya L ^c   Fuery, Caroline J ^c   Angibaud, Patrick ^a   Venet, Marc ^a   Sanz, Gerard ^a   Poignet, Herve ^a   Skrzat, Stacy ^d   Devine, Ann ^d   Wouters, Walter ^b   Bowden, Charles ^d  

^a Janssen Research Foundation   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c JOHNSON AND JOHNSON   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIN B; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN H RAS; PROTEIN K RASB; QUINOLINE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FEMALE; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN N RAS;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; PROTEIN ISOPRENYLATION; QUINOLONES; RAS PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035132538     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
2. Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase
3. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
4. Activation of Raf as a result of recruitment to the plasma membrane
5. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
6. rasis two step and involves carboxyl-methylation and carboxyterminal proteolysis
7. Cloning and characterization of a mammalian prenyl protein-specific protease
8. rasfarnesyl: Protein transferase by Cys-AAX peptides
9. Ras C-terminal processing enzymes: New drug targets?
10. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells
11. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
12. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes
13. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
14. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines
15. Polylysine, and CVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
16. v12proteins to farnesyltransferase inhibitors in Rat1 cells
17. Direct demonstration of geranylgeranylation and farnesylation of Ki-ras in vivo
18. K- and N-ras are geranylgeranylated in cells treated with farnesylprotein transferase inhibitors
19. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice
20. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion
21. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
22. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
23. RhoB alteration is necessary for the apoptotic and antineoplastic responses to farnesyltransferase inhibitors
24. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
25. Both farnesylated and geranylgeranylated rhoB inhibit malignant transformation and suppress human tumor growth in nude mice
26. Purification of ras farnesyl protein transferase
27. Rapid screening of mutant N-ras alleles by analysis of PCR-induced restriction sites: Allele specific restriction analysis (ASRA)
28. Farnesyltransferase inhibitors block the neurofibromatosis type I (NFI) malignant phenotype
29. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
30. Inhibition of the prenylation of K-Ras, but not H- or N-Ras is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase inhibitor and a geranylgeranyltransferase I inhibitor in human tumor cell lines
31. Mammalian protein geranylgeranyltransferase-I: Substrate specificity, kinetic mechanism, metal requirements and affinity labeling
32. Protein farnesyltransferase and geranylgeranyltransferase share a common α subunit
33. Evidence for a catalytic role of zinc in protein farnesyltransferase
34. Crystal structure of farnesyl protein transferase complexed with CaaX peptide and farnesyl diphosphate analogue
35. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
36. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
37. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells
38. Mouse mammary tumor virus Ki-rasB transgenic mic develop mammary carcinomas that can be growth-inhibited by a farnesyl: Protein transferase inhibitor
39. Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking
40. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
41. The phosphoinositide 3-OH-kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis